Is Can Fite Biopharma Stock a good buy in 2026, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NYSEMKT: CANF) stock is to Strong Buy CANF stock.
Out of 2 analysts, 1 (50%) are recommending CANF as a Strong Buy, 1 (50%) are recommending CANF as a Buy, 0 (0%) are recommending CANF as a Hold, 0 (0%) are recommending CANF as a Sell, and 0 (0%) are recommending CANF as a Strong Sell.
According to 2 Wall Street analysts that have issued a 1 year CANF price target, the average CANF price target is $7.50, with the highest CANF stock price forecast at $8.00 and the lowest CANF stock price forecast at $7.00.
On average, Wall Street analysts predict that Can Fite Biopharma's share price could reach $7.50 by Jul 2, 2027. The average Can Fite Biopharma stock price prediction forecasts a potential upside of 128.66% from the current CANF share price of $3.28.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.